Qelbree (viloxazine) and Strattera (atomoxetine) are both non-stimulant ADHD medicines with boxed warnings for suicidal thoughts, but they work through different mechanisms and Qelbree is the newer of the two, approved in 2021 versus Strattera’s 2002 approval. This guide compares their mechanisms, dosing, approved ages, and shared and distinct warnings.
This is general information, not medical advice.
Qelbree vs Strattera at a glance
| Qelbree (viloxazine) | Strattera (atomoxetine) | |
|---|---|---|
| Drug class | Serotonin-norepinephrine modulating agent (SNMA) | Selective norepinephrine reuptake inhibitor (SNRI) |
| Controlled substance | No | No |
| FDA-approved for | ADHD (ages 6+, adults) | ADHD (ages 6+, adults) |
| Initial US approval | 2021 | 2002 |
| Boxed warning | Suicidal thoughts and behaviors | Suicidal ideation in children/adolescents |
| Dosing frequency | Once daily | Once or twice daily |
| Generic available | No | Yes |
What each is approved for
Both are approved for ADHD in adults and children 6 and older, and neither has an additional indication in this comparison. Neither is a controlled substance, and neither carries the abuse/misuse boxed warning that stimulant ADHD drugs (Adderall, Vyvanse, Concerta, and the rest) carry.
How they work: different non-stimulant mechanisms
Strattera (atomoxetine) is described in its label as a selective norepinephrine reuptake inhibitor, meaning its primary pharmacological action is blocking the reuptake of norepinephrine specifically.
Qelbree (viloxazine) works differently at the receptor level; it’s classified as a serotonin-norepinephrine modulating agent, and its exact mechanism of action in ADHD is described in prescribing references as not fully understood, though it’s thought to work primarily through inhibiting norepinephrine reuptake while also having some effect on serotonin receptor activity, distinguishing it somewhat from atomoxetine’s more strictly norepinephrine-focused profile.
The two suicidality warnings, compared
Both carry a boxed warning for suicidal thoughts and behavior, but the specifics differ slightly. Strattera’s warning is specifically framed around children and adolescents, based on short-term studies showing increased risk of suicidal ideation in that age group, with no completed suicides observed in the clinical trials.
Qelbree’s boxed warning is written more broadly to cover suicidal thoughts and behaviors generally, based on clinical trials that found higher rates of suicidal thoughts and behavior among pediatric patients treated with Qelbree than those on placebo. The Qelbree label also specifically instructs prescribers to screen patients for a personal or family history of suicide, bipolar disorder, and depression before starting treatment, a more explicit pre-screening instruction than appears in Strattera’s label.
Additional distinguishing warnings
Strattera carries a specific warning about severe liver injury: the label instructs that it should be discontinued and not restarted in patients who develop jaundice or laboratory evidence of liver injury. This is a warning unique to atomoxetine among the two; Qelbree’s label does not carry a comparable hepatic warning of the same severity.
Qelbree, being newer, has less real-world long-term safety data accumulated compared with the two-decades-plus track record Strattera has amassed since 2002, a general consideration for any newer drug regardless of its specific label content.
Dosing
Strattera dosing is weight-based in patients under 70 kg, with initial, target, and maximum daily doses defined by body weight, generally started low and titrated over about 2 to 4 weeks; it can be dosed once daily in the morning or split into two doses (morning and late afternoon/early evening).
Qelbree is taken once daily, administered with or without food; the capsules must not be cut, crushed, or chewed. Common side effects reported in children 6 to 17 include sleepiness, tiredness, vomiting, irritability, decreased appetite, nausea, and trouble sleeping.
Side effects
Both share somnolence/sleepiness, decreased appetite, nausea, and sleep disruption as common adverse effects. Strattera’s side effect profile additionally documents effects on blood pressure and heart rate requiring monitoring, and effects on growth (height and weight) with long-term pediatric use, tracked through routine visits, similar to the monitoring recommended across the non-stimulant ADHD drug class generally.
Who each might suit
Factors that may point toward Strattera:
- A generic option is available, generally making it less expensive out of pocket
- A longer track record (approved since 2002) with more accumulated real-world safety data
- A history of anxiety alongside ADHD; its label notes it does not worsen anxiety in patients with comorbid anxiety disorders
Factors that may point toward Qelbree:
- A once-daily dosing preference without needing a split-dose schedule
- No suitable trial of Strattera due to liver-related concerns, since Qelbree does not carry the same hepatic injury warning
- Willingness to accept a newer drug with less accumulated long-term data in exchange for its specific mechanism or dosing profile
Frequently asked questions
Is Qelbree a stimulant?
No. Like Strattera, it’s a non-stimulant and is not a controlled substance.
Which has been on the market longer?
Strattera, approved in 2002. Qelbree was approved in 2021, so it has a much shorter track record.
Does Qelbree carry a liver injury warning like Strattera?
No. Strattera’s label carries a specific severe liver injury warning requiring discontinuation if jaundice or liver injury signs appear; Qelbree’s label does not carry a comparable hepatic warning.
Is a generic version of Qelbree available?
Not according to current information; Strattera (atomoxetine) does have generic versions available, which typically makes it less costly.
How long before either drug starts working?
Both are non-stimulants whose full benefit typically develops over several weeks rather than immediately, unlike stimulant ADHD medications.
What “newer drug, less data” actually means for patients
Qelbree’s 2021 approval means it has roughly two decades less accumulated real-world use than Strattera. This doesn’t mean it’s less safe based on current evidence, its approval trials specifically evaluated safety in over a thousand pediatric patients, including hundreds followed for 6 months or more and a smaller group for a full year, but it does mean rare side effects that only surface after millions of prescriptions have been filled (the kind that emerge from postmarketing surveillance over many years) simply haven’t had as much time to be detected with Qelbree as they have with Strattera. This is a general consideration with any newer drug, not a specific red flag unique to viloxazine.
Switching between the two
There’s no official cross-titration schedule published for switching between atomoxetine and viloxazine, since they’re different molecules without an established dose-equivalence table. A typical approach is to taper off one under medical supervision before starting the other at its own standard starting dose, rather than assuming any specific ratio between the two. Given that both carry suicidality warnings requiring close monitoring, any switch period deserves particularly close attention to mood and behavior changes.
Comorbid conditions worth discussing before choosing
Anxiety: Strattera’s label specifically notes it does not worsen anxiety in patients with ADHD and comorbid anxiety disorders, useful information for a common overlapping diagnosis. Qelbree’s label does not carry the same specific anxiety-related language, though this doesn’t necessarily mean it worsens anxiety; it simply hasn’t been studied and labeled the same way.
Bipolar disorder or depression history: Because Qelbree’s label specifically instructs screening for personal or family history of bipolar disorder and depression before starting treatment, given the suicidality signal, patients or families with either history in the family should raise this directly with the prescriber regardless of which non-stimulant is ultimately chosen.
Frequently asked questions (continued)
Is Qelbree safe for someone with a family history of bipolar disorder?
The label specifically instructs prescribers to screen for personal or family history of bipolar disorder, depression, and suicide before starting Qelbree, given its suicidality warning. This history should be discussed directly with the prescriber rather than avoided or downplayed.
Can I switch from Strattera to Qelbree directly?
There’s no official published conversion dose between the two. A typical approach is tapering off one under medical supervision before starting the other at its standard starting dose, with close mood monitoring during the transition.
Does either drug worsen anxiety?
Strattera’s label specifically states it does not worsen anxiety in ADHD patients with comorbid anxiety disorders. Qelbree’s label doesn’t carry equivalent specific language on this point.
References
- FDA. STRATTERA (atomoxetine hydrochloride) prescribing information (2007).
- FDA. STRATTERA prescribing information, updated (2017).
- FDA. QELBREE (viloxazine extended-release capsules) prescribing information (2021).
- DailyMed. QELBREE Medication Guide.
- Healthline. Qelbree vs. Strattera: How These Drugs Compare (2025).